---
title: "Astrazeneca debuts at the 8th China International Import Expo, announcing the expansion of its production layout in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264454292.md"
description: "Astrazeneca announced at the 8th China International Import Expo that it will expand its production layout in China, planning to invest approximately USD 136 million to enhance the production capacity of its Qingdao manufacturing base, particularly for inhalation aerosol production, to meet the needs of patients with respiratory diseases. In addition, Astrazeneca showcased two innovative oncology drugs approved in China this year and several innovative therapies in new disease areas"
datetime: "2025-11-05T13:49:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264454292.md)
  - [en](https://longbridge.com/en/news/264454292.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264454292.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264454292.md) | [繁體中文](https://longbridge.com/zh-HK/news/264454292.md)


# Astrazeneca debuts at the 8th China International Import Expo, announcing the expansion of its production layout in China

On November 5th, it was reported that AstraZeneca, a multinational pharmaceutical company that has participated for eight consecutive years, made its appearance at the 8th China International Import Expo. The company announced its plans to expand production in China and shared its latest achievements in sustainable development, showcasing several innovative drugs. On the first day of the expo, AstraZeneca signed a cooperation agreement with the Qingdao High-tech Industrial Development Zone Management Committee, announcing an additional investment of approximately $136 million to expand the production capacity of its Qingdao supply base. This expansion will further enhance AstraZeneca's capacity for inhalation aerosols, better meeting the treatment needs of patients with respiratory diseases such as asthma and COPD. Additionally, the Qingdao base project has adopted energy-saving technologies to achieve near-zero carbon operations. At this year's expo, AstraZeneca also showcased for the first time two innovative oncology drugs approved in China this year: QianKede® and Dazhuoyou®. Furthermore, several innovative therapies in newly explored disease areas were also presented at the booth

### Related Stocks

- [AstraZeneca PLC (AZN.US)](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

- [AstraZeneca says Efzimfotase alfa PH3 program show positive results](https://longbridge.com/en/news/281138062.md)
- [AstraZeneca hails positive results in tozorakimab lung disease trials](https://longbridge.com/en/news/280752841.md)
- [AstraZeneca Scores Pediatric Win While Adult Trial Falls Short In Rare Bone Disease](https://longbridge.com/en/news/281215876.md)
- [AstraZeneca COPD Breakthrough With Tozorakimab Adds Fresh Upside Question](https://longbridge.com/en/news/280851586.md)
- [Deutsche Bank  Keeps Their Sell Rating on AstraZeneca (AZN)](https://longbridge.com/en/news/280657628.md)